The following is for educational purposes only. For FDA-cleared INTRABEAM® Indications for Use, see indications 510k.
- Focusing on your patient
ZEISS helps you provide patients with treatment options in addition to the conventional standard of care. Radiation with INTRABEAM® from ZEISS enables an individual treatment that minimizes collateral tissue exposure with a shorter duration of the radiation therapy compared to external beam radiation therapy (EBRT).
- Targeted applications without delay
Local irradiation of the tumor or the tumor bed can be prescribed as a single treatment or as a boost treatment combined with external beam radiotherapy.
- Unifying proven IORT advantages in one solution
Low-energy X-rays have a high relative biological effectiveness due to the higher ionization density of radiation in tissue compared to megavolt X-rays. Additionally, due to the steep dose falloff, the tissue of interest is irradiated in a way that reduces collateral damage, which is a special characteristic of low-energy radiation. Therefore, radiation can be applied immediately to well-vascularized tissue after R0 resection and also after incomplete tumor resections in R1 and R2 scenarios.1, 2
- Made by ZEISS
Keep your clinical institution at the forefront of oncology with ZEISS as your experienced partner for medical equipment with innovative products and hundreds of installed systems around the world.
The ZEISS INTRABEAM System consists of: INTRABEAM PRS 500 with XRS, INTRABEAM Cart and NC32 INTRABEAM Floor Stand.
1 Liu, Q., Schneider, F., Ma, L., Wenz, F., & Herskind, C. (2013). Relative Biologic Effectiveness (RBE) of 50 kV X-rays Measured in a Phantom for Intraoperative Tumor-Bed Irradiation. International Journal of Radiation Oncology*Biology*Physics, 85(4), 1127–1133.
2 Eaton, D. J., & Duck, S. (2010). Dosimetry measurements with an intra-operative x-ray device. Physics in Medicine and Biology, 55(12), N359–N369.